Core Insights - Serina Therapeutics is presenting new data on its POZ-lipid technology at the 4th LNP Formulation & Process Development Summit, focusing on its potential to address challenges with anti-PEG antibodies in mRNA vaccines [1][2] - The POZ-lipid demonstrated no IgM or IgG antibody response in rats, contrasting with PEG-lipid standards that triggered a strong antibody response [2][3] - The absence of an immune response to POZ-lipid could lead to safer and more effective lipid nanoparticle formulations for gene therapy and RNA-based medicines [3] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates for neurological diseases and other indications [4] - The company utilizes its proprietary POZ Platform™ to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules and RNA-based therapeutics [4]
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit